Search Results for: MAPK8

Novel Interactant Symbol Name
Associated Pathways
Binding Drugs
Associated Diseases
MYC MYC proto-oncogene, bHLH transcription factor
  • Transcription of E2F targets under negative control by DREAM complex
  • Signaling by ALK
  • NOTCH1 Intracellular Domain Regulates Transcription
  • SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription
  • Constitutive Signaling by NOTCH1 PEST Domain Mutants
  • Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants
  • Binding of TCF/LEF:CTNNB1 to target gene promoters
  • MAPK6/MAPK4 signaling
  • Ub-specific processing proteases
  • Interleukin-4 and Interleukin-13 signaling
  • Cyclin E associated events during G1/S transition
  • Cyclin A:Cdk2-associated events at S phase entry
  • TFAP2 (AP-2) family regulates transcription of cell cycle factors
  • RUNX3 regulates WNT signaling
  • Estrogen-dependent gene expression
  • Transcriptional regulation of granulopoiesis
  • Regulation of CDH1 mRNA translation by microRNAs
  • Regulation of NFE2L2 gene expression
  • Regulation of PD-L1(CD274) transcription
  • Acetylsalicylic acid
  • Dimethyl sulfoxide
  • Doconexent
  • Nadroparin
  • Penile cancer
  • Breast cancer
  • Laryngeal cancer
  • Oral cancer
  • Multiple myeloma
  • Kaposi's sarcoma
  • Ovarian cancer
  • Choriocarcinoma
  • Acute lymphoblastic leukemia (ALL) (precursor T lymphoblastic leukemia)
  • Burkitt lymphoma
  • Small cell lung cancer
  • Osteosarcoma
  • Acute lymphoblastic leukemia (ALL) (precursor B lymphoblastic leukemia)
NCOA3 nuclear receptor coactivator 3
  • PPARA activates gene expression
  • Transcriptional regulation of white adipocyte differentiation
  • Transcriptional regulation of white adipocyte differentiation
  • Activation of anterior HOX genes in hindbrain development during early embryogenesis
  • MAPK6/MAPK4 signaling
  • Estrogen-dependent gene expression
  • MLL4 and MLL3 complexes regulate expression of PPARG target genes in adipogenesis and hepatic steatosis
  • MLL4 and MLL3 complexes regulate expression of PPARG target genes in adipogenesis and hepatic steatosis
NFATC3 nuclear factor of activated T cells 3
  • Calcineurin activates NFAT
  • Calcineurin activates NFAT
  • FCERI mediated Ca+2 mobilization
  • CLEC7A (Dectin-1) induces NFAT activation
NFATC4 nuclear factor of activated T cells 4
NFE2 nuclear factor, erythroid 2
  • RUNX1 regulates genes involved in megakaryocyte differentiation and platelet function
  • Factors involved in megakaryocyte development and platelet production
  • Factors involved in megakaryocyte development and platelet production
NFE2L2 NFE2 like bZIP transcription factor 2
  • Neddylation
  • Potential therapeutics for SARS
  • Regulation of HMOX1 expression and activity
  • Heme signaling
  • KEAP1-NFE2L2 pathway
  • KEAP1-NFE2L2 pathway
  • Nuclear events mediated by NFE2L2
  • GSK3B and BTRC:CUL1-mediated-degradation of NFE2L2
  • NFE2L2 regulating TCA cycle genes
  • NFE2L2 regulating inflammation associated genes
  • NFE2L2 regulating anti-oxidant/detoxification enzymes
  • NFE2L2 regulates pentose phosphate pathway genes
  • NFE2L2 regulating tumorigenic genes
  • NFE2L2 regulating MDR associated enzymes
  • NFE2L2 regulating ER-stress associated genes
  • Regulation of NFE2L2 gene expression
  • Regulation of NFE2L2 gene expression
  • Regulation of PD-L1(CD274) transcription
NKAPD1 NKAP domain containing 1
NR3C1 nuclear receptor subfamily 3 group C member 1
  • HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand
  • SUMOylation of intracellular receptors
  • PTK6 Expression
  • Regulation of RUNX2 expression and activity
  • FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes
  • Potential therapeutics for SARS
  • Regulation of NPAS4 gene transcription
  • Flunisolide
  • Diflorasone
  • Alclometasone
  • Medrysone
  • Amcinonide
  • Fluorometholone
  • Megestrol acetate
  • Levonorgestrel
  • Beclomethasone dipropionate
  • Progesterone
  • Spironolactone
  • Betamethasone
  • Desoximetasone
  • Fluticasone propionate
  • Fluocinolone acetonide
  • Ulobetasol
  • Triamcinolone
  • Prednisone
  • Flumethasone
  • Fludrocortisone
  • Norethisterone
  • Hydrocortisone
  • Mometasone
  • Hydrocortamate
  • Mifepristone
  • Clocortolone
  • Flurandrenolide
  • Prednisolone
  • Loteprednol etabonate
  • Rimexolone
  • Methylprednisolone
  • Clobetasol propionate
  • Fluocinonide
  • Prednicarbate
  • Fluoxymesterone
  • Budesonide
  • Dexamethasone
  • Desonide
  • Cortisone acetate
  • Paramethasone
  • Drospirenone
  • Ciclesonide
  • Hexane-1,6-Diol
  • Aldosterone
  • ORG-34517
  • Difluprednate
  • Ulipristal
  • Fluticasone furoate
  • Tixocortol
  • Difluocortolone
  • Gestrinone
  • Deflazacort
  • Onapristone
  • Cortivazol
  • Clobetasone
  • Fluticasone
  • Mometasone furoate
  • Hydrocortisone aceponate
  • Hydrocortisone acetate
  • Hydrocortisone butyrate
  • Hydrocortisone cypionate
  • Hydrocortisone phosphate
  • Hydrocortisone probutate
  • Hydrocortisone valerate
  • Segesterone acetate
  • Prednisolone phosphate
  • Dexamethasone acetate
  • Betamethasone phosphate
  • Prednisolone acetate
  • 46,XX disorders of sex development (Disorders related to androgen excess), including: Congenital adrenal hyperplasias; Glucocorticoid resistance; Aromatase deficiency
NR4A1 nuclear receptor subfamily 4 group A member 1
  • AKT phosphorylates targets in the nucleus
  • Nuclear Receptor transcription pathway
  • Constitutive Signaling by AKT1 E17K in Cancer
PAX2 paired box 2
  • Formation of intermediate mesoderm
  • Formation of the nephric duct
  • Formation of the ureteric bud
  • Renal coloboma syndrome (RCS); Papillorenal syndrome
PDPK1 3-phosphoinositide dependent protein kinase 1
  • GPVI-mediated activation cascade
  • GPVI-mediated activation cascade
  • PIP3 activates AKT signaling
  • Activation of AKT2
  • Downstream TCR signaling
  • Role of LAT2/NTAL/LAB on calcium mobilization
  • FCERI mediated NF-kB activation
  • Integrin signaling
  • CD28 dependent PI3K/Akt signaling
  • G beta:gamma signalling through PI3Kgamma
  • RSK activation
  • VEGFR2 mediated vascular permeability
  • VEGFR2 mediated cell proliferation
  • CLEC7A (Dectin-1) signaling
  • RHO GTPases activate PKNs
  • Constitutive Signaling by AKT1 E17K in Cancer
  • Regulation of TP53 Degradation
  • Estrogen-stimulated signaling through PRKCZ
  • Estrogen-stimulated signaling through PRKCZ
  • SARS-CoV-1 targets host intracellular signalling and regulatory pathways
  • SARS-CoV-2 targets host intracellular signalling and regulatory pathways
  • High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells
  • Celecoxib
  • Inositol 1,3,4,5-Tetrakisphosphate
  • 7-Hydroxystaurosporine
  • Bisindolylmaleimide VIII
  • Staurosporine
  • Bisindolylmaleimide I
  • Dexfosfoserine
  • 10,11-dimethoxy-4-methyldibenzo[c,f]-2,7-naphthyridine-3,6-diamine
  • 5-HYDROXY-3-[(1R)-1-(1H-PYRROL-2-YL)ETHYL]-2H-INDOL-2-ONE
  • 1-{2-OXO-3-[(1R)-1-(1H-PYRROL-2-YL)ETHYL]-2H-INDOL-5-YL}UREA
  • 2-(1H-imidazol-1-yl)-9-methoxy-8-(2-methoxyethoxy)benzo[c][2,7]naphthyridin-4-amine
  • 3-(1H-indol-3-yl)-4-(1-{2-[(2S)-1-methylpyrrolidinyl]ethyl}-1H-indol-3-yl)-1H-pyrrole-2,5-dione
  • 3-[1-(3-AMINOPROPYL)-1H-INDOL-3-YL]-4-(1H-INDOL-3-YL)-1H-PYRROLE-2,5-DIONE
  • Fostamatinib
PIAS2 protein inhibitor of activated STAT 2
  • Activation of anterior HOX genes in hindbrain development during early embryogenesis
PIK3R1 phosphoinositide-3-kinase regulatory subunit 1
  • PI3K Cascade
  • IRS-mediated signalling
  • GPVI-mediated activation cascade
  • Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
  • PI3K events in ERBB4 signaling
  • PIP3 activates AKT signaling
  • Interleukin-7 signaling
  • Interleukin-7 signaling
  • Signaling by SCF-KIT
  • Synthesis of PIPs at the plasma membrane
  • GAB1 signalosome
  • Signaling by cytosolic FGFR1 fusion mutants
  • Downstream signal transduction
  • PI3K events in ERBB2 signaling
  • PI3K/AKT activation
  • Signaling by ALK
  • Downstream TCR signaling
  • Role of phospholipids in phagocytosis
  • Tie2 Signaling
  • Constitutive Signaling by Aberrant PI3K in Cancer
  • DAP12 signaling
  • Role of LAT2/NTAL/LAB on calcium mobilization
  • Nephrin family interactions
  • CD28 dependent PI3K/Akt signaling
  • G alpha (q) signalling events
  • GP1b-IX-V activation signalling
  • VEGFA-VEGFR2 Pathway
  • VEGFA-VEGFR2 Pathway
  • Interleukin-3, Interleukin-5 and GM-CSF signaling
  • Constitutive Signaling by EGFRvIII
  • PI-3K cascade:FGFR1
  • PI-3K cascade:FGFR2
  • PI-3K cascade:FGFR3
  • PI-3K cascade:FGFR4
  • Signaling by FGFR2 in disease
  • Signaling by FGFR4 in disease
  • Signaling by FGFR1 in disease
  • Signaling by FGFR3 in disease
  • RAF/MAP kinase cascade
  • Interleukin-4 and Interleukin-13 signaling
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • MET activates PI3K/AKT signaling
  • RET signaling
  • RHOA GTPase cycle
  • Extra-nuclear estrogen signaling
  • RHOB GTPase cycle
  • RHOC GTPase cycle
  • CDC42 GTPase cycle
  • RAC1 GTPase cycle
  • RAC2 GTPase cycle
  • RHOD GTPase cycle
  • RHOG GTPase cycle
  • RHOJ GTPase cycle
  • RHOU GTPase cycle
  • RAC3 GTPase cycle
  • RHOV GTPase cycle
  • Erythropoietin activates Phosphoinositide-3-kinase (PI3K)
  • Erythropoietin activates Phosphoinositide-3-kinase (PI3K)
  • Activated NTRK2 signals through PI3K
  • RHOF GTPase cycle
  • Interleukin receptor SHC signaling
  • Regulation of signaling by CBL
  • Regulation of signaling by CBL
  • Activated NTRK3 signals through PI3K
  • FLT3 Signaling
  • FLT3 Signaling
  • Signaling by ERBB2 KD Mutants
  • Signaling by ERBB2 ECD mutants
  • Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants
  • Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants
  • Signaling by PDGFRA extracellular domain mutants
  • Signaling by CSF1 (M-CSF) in myeloid cells
  • RND3 GTPase cycle
  • RND2 GTPase cycle
  • RND1 GTPase cycle
  • Signaling by FLT3 fusion proteins
  • Signaling by FLT3 fusion proteins
  • Signaling by FLT3 ITD and TKD mutants
  • Signaling by FLT3 ITD and TKD mutants
  • Signaling by ALK fusions and activated point mutants
  • Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
  • Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
  • Signaling by LTK in cancer
  • Signaling by LTK
  • Co-stimulation by ICOS
  • SF1126
  • Enzastaurin
  • Wortmannin
PKMYT1 protein kinase, membrane associated tyrosine/threonine 1
  • Polo-like kinase mediated events
  • Cyclin A/B1/B2 associated events during G2/M transition
  • G2/M DNA replication checkpoint
  • Fostamatinib
PNRC1 proline rich nuclear receptor coactivator 1
PPARG peroxisome proliferator activated receptor gamma
  • PPARA activates gene expression
  • Transcriptional regulation of white adipocyte differentiation
  • Transcriptional regulation of white adipocyte differentiation
  • Nuclear Receptor transcription pathway
  • SUMOylation of intracellular receptors
  • Regulation of PTEN gene transcription
  • Regulation of PTEN gene transcription
  • MECP2 regulates transcription factors
  • Transcriptional regulation of brown and beige adipocyte differentiation by EBF2
  • alpha-Linolenic acid
  • Icosapent
  • Troglitazone
  • Mesalazine
  • Valproic acid
  • Indomethacin
  • Rosiglitazone
  • Fenoprofen
  • Nateglinide
  • Clofazimine
  • Repaglinide
  • Telmisartan
  • Balsalazide
  • Ibuprofen
  • Glipizide
  • Amiodarone
  • Pioglitazone
  • Mitiglinide
  • Bezafibrate
  • Flufenamic acid
  • Resveratrol
  • Phthalic Acid
  • Capric acid
  • Doconexent
  • Oleic Acid
  • (S)-3-(4-(2-Carbazol-9-Yl-Ethoxy)-Phenyl)-2-Ethoxy-Propionic Acid
  • 2-{5-[3-(6-BENZOYL-1-PROPYLNAPHTHALEN-2-YLOXY)PROPOXY]INDOL-1-YL}ETHANOIC ACID
  • Reglitazar
  • Elafibranor
  • AMG-131
  • CLX-0921
  • Muraglitazar
  • Ertiprotafib
  • Ragaglitazar
  • Tesaglitazar
  • (2S)-3-(1-{[2-(2-CHLOROPHENYL)-5-METHYL-1,3-OXAZOL-4-YL]METHYL}-1H-INDOL-5-YL)-2-ETHOXYPROPANOIC ACID
  • (9Z,11E,13S)-13-hydroxyoctadeca-9,11-dienoic acid
  • 2-{5-[3-(7-PROPYL-3-TRIFLUOROMETHYLBENZO[D]ISOXAZOL-6-YLOXY)PROPOXY]INDOL-1-YL}ETHANOIC ACID
  • (4S,5E,7Z,10Z,13Z,16Z,19Z)-4-hydroxydocosa-5,7,10,13,16,19-hexaenoic acid
  • (5R,6E,8Z,11Z,14Z,17Z)-5-hydroxyicosa-6,8,11,14,17-pentaenoic acid
  • (8E,10S,12Z)-10-hydroxy-6-oxooctadeca-8,12-dienoic acid
  • (8R,9Z,12Z)-8-hydroxy-6-oxooctadeca-9,12-dienoic acid
  • 9(S)-HODE
  • difluoro(5-{2-[(5-octyl-1H-pyrrol-2-yl-kappaN)methylidene]-2H-pyrrol-5-yl-kappaN}pentanoato)boron
  • (2S)-2-ETHOXY-3-{4-[2-(10H-PHENOXAZIN-10-YL)ETHOXY]PHENYL}PROPANOIC ACID
  • 3-(5-methoxy-1H-indol-3-yl)propanoic acid
  • Indeglitazar
  • (2S)-2-(4-ethylphenoxy)-3-phenylpropanoic acid
  • 2-chloro-5-nitro-N-phenylbenzamide
  • (2S)-2-(biphenyl-4-yloxy)-3-phenylpropanoic acid
  • 3-[5-(2-nitropent-1-en-1-yl)furan-2-yl]benzoic acid
  • 2-[(2,4-DICHLOROBENZOYL)AMINO]-5-(PYRIMIDIN-2-YLOXY)BENZOIC ACID
  • (5E,14E)-11-oxoprosta-5,9,12,14-tetraen-1-oic acid
  • 3-FLUORO-N-[1-(4-FLUOROPHENYL)-3-(2-THIENYL)-1H-PYRAZOL-5-YL]BENZENESULFONAMIDE
  • Triclosan
  • (2S)-2-(4-chlorophenoxy)-3-phenylpropanoic acid
  • Aleglitazar
  • Clinofibrate
  • Cannabidiol
  • Lobeglitazone
  • Ciglitazone
  • Dexibuprofen
  • Omega-3 fatty acids
  • Curcumin
  • Arhalofenate
  • Isoflavone
  • Naveglitazar
  • Fenofibric acid
  • Fish oil
  • Medical Cannabis
  • Nabiximols
  • Darglitazone
  • Curcumin sulfate
  • Thyroid cancer
  • Familial partial lipodystrophy (FPL), including the following four diseases: Kobberling-type lipodystrophy (FPLD1); Dunnigan-type lipodystrophy (FPLD2); Dunnigan-like lipodystrophy (FPLD3); AKT2 associated lipodystrophy
  • Type II diabetes mellitus
PRKD1 protein kinase D1
  • Sphingolipid de novo biosynthesis
  • Bryostatin 1
  • Fostamatinib
PRKDC protein kinase, DNA-activated, catalytic subunit
  • Cytosolic sensors of pathogen-associated DNA
  • IRF3-mediated induction of type I IFN
  • Nonhomologous End-Joining (NHEJ)
  • E3 ubiquitin ligases ubiquitinate target proteins
  • Caffeine
  • SF1126
PTPN20 protein tyrosine phosphatase non-receptor type 20
  • Interleukin-37 signaling
PXN paxillin
  • GAB1 signalosome
  • VEGFA-VEGFR2 Pathway
  • Smooth Muscle Contraction
  • Localization of the PINCH-ILK-PARVIN complex to focal adhesions
  • Regulation of cytoskeletal remodeling and cell spreading by IPP complex components
  • PTK6 Regulates RHO GTPases, RAS GTPase and MAP kinases
  • Regulation of MITF-M-dependent genes involved in extracellular matrix, focal adhesion and epithelial-to-mesenchymal transition

Page 13 out of 15 pages